Drug Trial Radar · NCT03761017
MGD019 DART® Protein in Unresectable/Metastatic Cancer
Last checked: Nov 19, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
162
Actual
Start
Dec 12, 2018
Primary completion
Aug 29, 2024
Study completion Jan 27, 2025
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- First posted
- Dec 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is determined, a Cohort Expansion Phase will be enrolled to further characterize safety and initial anti-tumor activity in patients with specific tumor types anticipated to be sensitive to dual checkpoint blockade.
Conditions
- Squamous Cell Non Small Cell Lung Cancer
- Prostate Cancer Metastatic
- Cutaneous Melanoma
- Colorectal Cancer
- Advanced Cancer
- Solid Tumor, Adult
Interventions
LorigerlimabBiological
Bispecific DART protein binding PD-1 and CTLA-4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: 30 days after last dose
Locations
39 sites in 5 countries. Site status is shown where the registry gives one.
University of Chicago Medical Center
Chicago, Illinois
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
START Midwest
Grand Rapids, Michigan
Oncology Hematology West p.c. dba Nebraska Cancer Specialists
Grand Island, Nebraska
Nebraska Cancer Specialists
Omaha, Nebraska
Providence Portland Medical Center
Portland, Oregon
UPMC Hillman Cancer Center
Camp Hill, Pennsylvania
UPMC Hillman Cancer Center
Carlisle, Pennsylvania
UPMC Hillman Cancer Center
Erie, Pennsylvania
UPMC Pinnacle Harrisburg
Harrisburg, Pennsylvania
UPMC Pinnacle - Community Osteopathic Medical Sciences Pavilion (MSP)
Harrisburg, Pennsylvania
UPMC Pinnacle - Ortenzio Cancer Center (OCC)
Mechanicsburg, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
UPMC Hillman Cancer Center at UPMC Memorial
York, Pennsylvania
The Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Complex Oncology Center - Burgas" EOOD, Department of Medical Oncology
Burgas, Bulgaria
Multiprofile Hospital for Active Treatment-Uni Hospital
Panagyurishte, Bulgaria
Multiprofile Hospital for Active Treatment "Heart and Brain"" EAD, Clinic of Medical Oncology
Pleven, Bulgaria
Complex Oncology Center - Ruse EOOD
Rousse, Bulgaria
University Mulitprofile Hospital for Active Treatment "Sv. Ivan Rilski
Sofia, Bulgaria
University Clinical Centre, Early Clinical Trials Unit
Gdansk, Poland
Pratia MCM Krakow
Krakow, Poland
Europejskie Centrum Zdrowia Otwock
Otwock, Poland
Med-Polonia Sp. z.o.o.
Poznan, Poland
LUX MED Onkologia Sp. z.o.o.
Warsaw, Poland
Narodowy Instytut Onkologii im
Warsaw, Poland
Mazovian Onkological Hospital
Wieliszew, Poland
Hospital Ruber Internacional
Madrid, Spain
Hospital Universitario La Princesa
Madrid, Spain
ICO Badalona / Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
Communal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro
Dnipro, Ukraine
Communal Non-Profit Enterprise "Regional Center of Oncology", Oncosurgical Department of Head and Neck
Kharkiv, Ukraine
Communal Nonprofit Enterprise "Regional Clinical Oncology Center of Kirovohrad Regional Council"
Kirovohrad, Ukraine
Kyiv City Clinical Oncological Centre
Kyiv, Ukraine
National Cancer Institute of Ukraine
Kyiv, Ukraine
Sumy Clinical Oncological Hospital
Sumy, Ukraine
Communal Nonprofit Enterprise "Podilsky Regional Center of Oncology"
Vinnytsia, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.